WHAT'S KNOWN ON THIS SUBJECT: Extremely preterm infants who receive antihypotensive therapy have worse outcomes than untreated infants. The reasons for this are not clear. High-quality randomized trials have not been performed to date because of logistical challenges, thereby necessitating alternative methods of investigation.
The intrinsically abnormal condition of extremely preterm infants and their evolving complex physiology make it difficult to identify an acceptable range of blood pressure (BP) values in the immediate postnatal period. Currently, there is not a validated or widely accepted definition of hypotension in this population. 1 Difficulty with assessing organ perfusion, multiple disease processes, and unpredictable adaptation to extrauterine life also make deciding when to institute antihypotensive therapy challenging. Consequently, BP management is highly variable. 2, 3 The frequency of antihypotensive therapy use during the transition from intrauterine to postnatal life ranges from 29% to 82% across NICUs. 3, 4 Extremely preterm infants who receive these therapies have higher mortality and morbidity rates versus untreated gestational age (GA) matched infants, [4] [5] [6] [7] [8] [9] [10] [11] [12] but it is unclear whether these worse outcomes are due to the cause of low BP, associated organ hypoperfusion, therapy for low BP, or a combination of these and other factors. Interpretation of BP management data is also complicated by methodologic limitations and confounding factors, both known and unknown. 1 Randomized placebo controlled trials investigating BP management in this population are lacking. 1 This is at least partly due to the many challenges of studying critical therapeutic interventions shortly after birth in such a vulnerable patient population. These include the inability to obtain timely and ethically valid informed consent, insufficient physician equipoise, identification of appropriate inclusion and exclusion criteria, and enrollment or selection biases. [13] [14] [15] [16] Difficulties with randomized placebo controlled trials have led to alternative methods of investigating BP management in preterm infants. 1, [7] [8] [9] 17 However, these studies are limited by their retrospective design, small sample sizes, and inconsistent definition of low BP. Currently, there is no known BP threshold below which extremely preterm infants are at an increased risk for a poor outcome and little evidence that antihypotensive therapy improves outcomes for infants with low BP, however defined. The objectives of this study were to prospectively examine BP management in the first 24 hours for extremely preterm infants and to investigate the relationship between recorded BP values, antihypotensive therapy use, and in-hospital infant outcomes in an effort to identify a BP threshold below which therapy may be beneficial.
METHODS
This was a prospective observational study of inborn extremely preterm infants 23 0/7 to 26 6/7 weeks' GA born at 1 of 16 academic centers of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (NRN). Infants were excluded if they died in the delivery room, had a major birth defect, or had intensive care withheld or withdrawn shortly after birth because the clinical care team felt the situation was hopeless. Research personnel used study-specific data forms to record hourly BP values and the administration of all antihypotensive therapies in the first 24 hours. BP values were obtained from an arterial catheter when available or by oscillography. Antihypotensive therapy was defined as receipt of a fluid bolus (at least 10 mL/kg of crystalloid), dopamine, dobutamine, epinephrine, hydrocortisone, vasopressin, or any blood product. Therapies were administered at the discretion of the clinical care team. Data were recorded on maternal demographics, the infant's initial condition, and in-hospital outcomes. Standard definitions were applied for intraventricular hemorrhage (IVH), 18 necrotizing enterocolitis, 19 retinopathy of prematurity (ROP), 20 and bronchopulmonary dysplasia. 21 This study was approved by the institutional review board at each participating center and was conducted either with informed parent consent for each infant before enrollment or with a waiver of consent from the center' s institutional review board. Associations between antihypotensive therapy and in-hospital outcomes were examined by using logistic models with a random intercept for NRN center while controlling for GA, illness severity, and the number of low BP values. Illness severity was defined a priori as the cumulative number of the following: a positive initial blood culture, an initial hematocrit #30%, a 1-minute Apgar score of #3, a pH ,7.10 in the first 24 hours, or need for delivery room chest compressions. Regression analysis was used to investigate the relationship between NRN center variability in the frequency of low BP values and the rate of antihypotensive therapy administration and to investigate the impact of NRN center variability in the rate of antihypotensive therapy administration on patient outcomes.
RESULTS
From July 21, 2010, to January 21, 2011, there were 367 infants enrolled, including 203 (55%) infants who received $1 antihypotensive therapy and 104 (28%) who received a vasoactive drug (Fig 1) . Fifteen enrolled infants (8 untreated, 7 treated) died in the first 24 hours. Of the 203 treated infants, 135 (67%) received a fluid bolus, 102 (50%) received a blood product, and 92 (45%), 25 (12%), and 18 (9%) received dopamine, hydrocortisone, and dobutamine, respectively. One patient received vasopressin. Many infants given a vasoactive drug also received a fluid bolus or blood product. The frequency of antihypotensive therapy use was inversely related to birth weight (P , .001) and GA (P , .001); 130 (64%) infants with a birth weight #750 g received therapy versus 73 (45%) infants with a birth weight of 750 to 1000 g and 88 (66%) infants born at 23 to 24 weeks' GA received therapy versus 115 (49%) infants born at 25 to 26 weeks' GA. Some, but not all, baseline characteristics differed between the 164 untreated infants and the 203 infants who received therapy (Table 1) . In-hospital outcomes for these groups are presented in Table 2 . The significant difference in the rate of survival to hospital discharge between the 2 groups was primarily due to a higher mortality rate after the first postnatal week for infants who received therapy (19% vs 11%) as the rate of survival to 1 week was not significantly different between groups. Logistic regression analysis with a random intercept for center controlling for GA, severity of illness, and the number of low BP values did not show any significant effects of antihypotensive therapy on rates of IVH or grade III/IV IVH, ROP, morbidityfree survival to hospital discharge (morbidity: necrotizing enterocolitis, ROP, bronchopulmonary dysplasia, grade III/IV IVH, or cystic periventricular
FIGURE 1
Extremely preterm infant study enrollment including classification by study group. ARTICLE leukomalacia), or survival through postnatal day 7 or until hospital discharge (P . .05 for all analyses, data not shown). Results were unchanged for each of the 15 definitions of low BP, when analysis was restricted to only infants with $1 low BP value, and when only invasive BP values were used (data not shown). There was not a definition of low BP identified for which infants who received therapy had improved rates of IVH, ROP, survival, or morbidity-free survival.
There was significant variation across NRN centers in the rate of antihypotensive therapy administration (P , .01), incidence of low BP (P , .01 for all definitions of low BP), and rate of survival to hospital discharge (P , .01; Fig 3) . With regression analysis, the center frequency of antihypotensive therapy administration was not significantly associated with the center incidence of low BP for any of the definitions of low BP investigated (P . 
DISCUSSION
In this prospective study of 367 extremely preterm infants, 55% received an antihypotensive therapy and 28% received a vasoactive drug. For each definition of low BP investigated, the likelihood of receiving therapy increased with the number of low BP values recorded. Antihypotensive therapy was often provided to infants without low BP and, paradoxically, not prescribed to infants with low BP. The observation that the NRN center rate of therapy was not significantly related to the center incidence of low BP is additional evidence that factors other than BP values contributed to the decision to provide antihypotensive therapy. Degree of prematurity and infant size appeared to influence this decision as the likelihood of receiving treatment was inversely related to GA and birth weight. In-hospital outcomes were not improved with therapy for any of the 15 definitions of low BP investigated, including those with $3 low BP values.
Results from the current study are consistent with previous investigations. [3] [4] [5] 10, 17, 22 In a study by Laughon et al, 82% of infants 23 to 27 weeks' GA received an antihypotensive therapy, including 34% who received a vasopressor. 3 Although that study had some limitations that do not apply to the current one, the findings for each were similar in that the rate of therapy use varied across NICUs; smaller, less mature infants were more likely to receive treatment; and the decision to provide treatment was strongly influenced by which center provided care. Other studies compared outcomes Two prospective interventional studies are in their early phases (Clinicaltrials.gov NCT01482559 and NCT01434251), but results are not expected from either before 2016. The prospective data collection, number of infants enrolled, and detailed data analysis plan of this study provide some of the strongest data to date regarding BP management in extremely preterm infants.
Despite the lack of evidence supporting the routine use of any antihypotensive No Therapy (n = 164) Administered Therapy (n = 203) P Value Necrotizing enterocolitis requiring surgery, n (%) 11 (7) 16 (8) .92
Bronchopulmonary dysplasia, n (%) 75 (46) 92 (45) .26 Cystic periventricular leukomalacia, n (%) 7 (4) 11 (5) .60
Intervention for ROP, n (%) 13 (8) 31 (15) .03 (Any) IVH, n (%)
43 (26) 83 (41) ,.01 Grade 3/4 IVH, n (%)
18 (11) 44 (22) ,
.02 Morbidity-free survival, a n (%) 24 (15) 11 (5) ,.01
a Morbidities: necrotizing enterocolitis, ROP, bronchopulmonary dysplasia, grade 3 or 4 IVH, or periventricular leukomalacia.
FIGURE 3
Center variation in the rate of antihypotensive therapy administration, frequency of low BP, and incidence of hospital survival.
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